Cargando…
Levocarnitine for valproate-induced hyperammonemia in the psychiatric setting: A case series and literature review
INTRODUCTION: Hyperammonemia is a potential adverse effect of valproic acid (VPA) therapy, which is often asymptomatic but can lead to severe, life-threatening encephalopathy. Carnitine deficiency due to VPA is the proposed mechanism for hyperammonemia and the development of VPA-induced hyperammonem...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
College of Psychiatric & Neurologic Pharmacists
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007637/ https://www.ncbi.nlm.nih.gov/pubmed/29955560 http://dx.doi.org/10.9740/mhc.2018.05.148 |